Treatment of short bowel syndrome patients with colon-in-continuity
AssigneeNPS Pharmaceuticals, Inc.
InventorsElizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Life of this patent
Estimating the term…
Abstract
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Claims12
A method of decreasing fecal wet weight of a patient having short bowel syndrome, who receives parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to decrease the fecal wet weight of said patient compared to fecal wet weight of said patient before said dosing regimen.
Dependencies are inferred from the claim text.